Lactobacilli and Bifidobacterium as anti-atherosclerotic agents

被引:2
|
作者
Abdi, Milad [1 ]
Ghaleh, Hadi Esmaeili Gouvarchin [2 ]
Ranjbar, Reza [3 ]
机构
[1] Kerman Univ Med Sci, Res Ctr Trop & Infect Dis, Kerman, Iran
[2] Baqiyatallah Univ Med Sci, Appl Virol Res Ctr, Tehran, Iran
[3] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst, Mol Biol Res Ctr, Tehran, Iran
关键词
Atherosclerosis; Bifidobacterium; Hypercholesterolemia; Inflammation; Lactobacilli; Oxidative stress; TMAO; TRIMETHYLAMINE N-OXIDE; BILE-SALT HYDROLASE; CHAIN FATTY-ACIDS; LIVER-X-RECEPTOR; CHOLESTEROL-LOWERING EFFICACY; PICK C1-LIKE 1; LIPID PROFILE; OXIDATIVE STRESS; SERUM-CHOLESTEROL; RISK-FACTORS;
D O I
10.22038/IJBMS.2022.63860.14073
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Atherosclerosis is the thickening or hardening of the arteries which is caused by a buildup of atheromatous plaque in the inner lining of an artery. Hypercholesterolemia, inflammation, oxidative stress, and trimethylamine N-oxide (TMAO) are important risk factors for atherosclerosis. Therefore, this study aimed to review the anti-atherosclerotic effects of Lactobacilli and Bifidobacterium via improving lipid profile and reducing the effects of oxidative stress, inflammation, and TMAO. To prepare the present review, several databases such as Scopus, PubMed, and Google Scholar were searched, and relevant articles from 1990 until 2022 were selected and reviewed. The present review showed that Lactobacilli and Bifidobacterium reduce the risk of atherosclerosis in both in vitro and in vivo studies by breaking down or altering cholesterol metabolism with the help of their by-products and by reducing inflammation and oxidative stress and TMAO. Consumption of Lactobacilli and Bifidobacterium can be useful in prevention of atherosclerosis.
引用
收藏
页码:934 / 946
页数:13
相关论文
共 50 条
  • [41] Advances in the Anti-Atherosclerotic Mechanisms of Epigallocatechin Gallate
    Liu, Yihui
    Long, Yiling
    Fang, Jun
    Liu, Gang
    NUTRIENTS, 2024, 16 (13)
  • [42] Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
    Sobenin, Igor A.
    Chistiakov, Dimitry A.
    Bobryshev, Yuri V.
    Orekhov, Alexander N.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (33) : 5954 - 5962
  • [43] Endothelial function for the evaluation of anti-atherosclerotic drugs
    Okumura, Kenji
    Cheng, Xian Wu
    HYPERTENSION RESEARCH, 2010, 33 (08) : 780 - 781
  • [44] Anti-Atherosclerotic and Anti-Inflammatory Actions of Sesame Oil
    Narasimhulu, Chandrakala Aluganti
    Selvarajan, Krithika
    Litvinov, Dmitry
    Parthasarathy, Sampath
    JOURNAL OF MEDICINAL FOOD, 2015, 18 (01) : 11 - 20
  • [45] Molecular Aspects of Anti-Atherosclerotic Effects of Short Peptides
    V. Kh. Khavinson
    N. S. Lin’kova
    E. V. Evlashkina
    A. O. Durnova
    K. L. Kozlov
    O. E. Gutop
    Bulletin of Experimental Biology and Medicine, 2014, 158 : 159 - 163
  • [46] Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
    Hetherington, Isabella
    Totary-Jain, Hana
    MOLECULAR THERAPY, 2022, 30 (10) : 3106 - 3117
  • [47] SINDHOORAM,ANNA,PAVALA - AN ANTI-ATHEROSCLEROTIC INDIAN DRUG
    SHANMUGASUNDARAM, KR
    SEETHAPATHY, PG
    SHANMUGASUNDARAM, ERB
    JOURNAL OF ETHNOPHARMACOLOGY, 1983, 7 (03) : 247 - 265
  • [48] Potential Use of Dendritic Cells for Anti-Atherosclerotic Therapy
    Van Brussel, Ilse
    Schrijvers, Dorien M.
    Van Vre, Emily A.
    Bult, Hidde
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (33) : 5873 - 5882
  • [49] The potential anti-atherosclerotic effect of itraconazole a medical hypothesis
    Feily, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 (08) : 552 - 553
  • [50] Viral serine protease inhibitors as anti-atherosclerotic therapy
    Bot, Ilze
    van Berkel, Theo Jc
    Al Biessen, Erik
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (09) : 729 - 735